case report | sciencenewsnet.in

Breaking News

Structural Safety Monitoring of Buildings with Color Variations

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

05 Nov, 2024

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

November 4, 2024 sarah JonasResearch Results

A new case report published in Annals of Internal Medicine describes the success of human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a patient with HER2-expressing treatment-emergent neuroendocrine prostate cancer (t-NEPC).